Global Hereditary Angioedema Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
Page: 95
Published Date: 26 Aug 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Hereditary Angioedema Drug market size was valued at USD 764.5 million in 2022 and is forecast to a readjusted size of USD 1188.6 million by 2029 with a CAGR of 6.5% during review period.
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Hereditary Angioedema Drug industry chain, the market status of Retail Pharmacies (C1 Esterase Inhibitor, Kallikrein Inhibitor), Hospital Pharmacies (C1 Esterase Inhibitor, Kallikrein Inhibitor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Hereditary Angioedema Drug.
Regionally, the report analyzes the Hereditary Angioedema Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Hereditary Angioedema Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Hereditary Angioedema Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Hereditary Angioedema Drug industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., C1 Esterase Inhibitor, Kallikrein Inhibitor).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Hereditary Angioedema Drug market.
Regional Analysis: The report involves examining the Hereditary Angioedema Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Hereditary Angioedema Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Hereditary Angioedema Drug:
Company Analysis: Report covers individual Hereditary Angioedema Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Hereditary Angioedema Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Retail Pharmacies, Hospital Pharmacies).
Technology Analysis: Report covers specific technologies relevant to Hereditary Angioedema Drug. It assesses the current state, advancements, and potential future developments in Hereditary Angioedema Drug areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Hereditary Angioedema Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Hereditary Angioedema Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Market segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Major players covered
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hereditary Angioedema Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hereditary Angioedema Drug, with price, sales, revenue and global market share of Hereditary Angioedema Drug from 2018 to 2023.
Chapter 3, the Hereditary Angioedema Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hereditary Angioedema Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Hereditary Angioedema Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hereditary Angioedema Drug.
Chapter 14 and 15, to describe Hereditary Angioedema Drug sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Hereditary Angioedema Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Hereditary Angioedema Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 C1 Esterase Inhibitor
1.3.3 Kallikrein Inhibitor
1.3.4 Selective Bradykinin B2 Receptor Antagonist
1.4 Market Analysis by Application
1.4.1 Overview: Global Hereditary Angioedema Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Retail Pharmacies
1.4.3 Hospital Pharmacies
1.4.4 Online Pharmacies
1.5 Global Hereditary Angioedema Drug Market Size & Forecast
1.5.1 Global Hereditary Angioedema Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Hereditary Angioedema Drug Sales Quantity (2018-2029)
1.5.3 Global Hereditary Angioedema Drug Average Price (2018-2029)
2.1 Pharming Group NV
2.1.1 Pharming Group NV Details
2.1.2 Pharming Group NV Major Business
2.1.3 Pharming Group NV Hereditary Angioedema Drug Product and Services
2.1.4 Pharming Group NV Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pharming Group NV Recent Developments/Updates
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Hereditary Angioedema Drug Product and Services
2.2.4 Takeda Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Takeda Recent Developments/Updates
2.3 CSL Limited
2.3.1 CSL Limited Details
2.3.2 CSL Limited Major Business
2.3.3 CSL Limited Hereditary Angioedema Drug Product and Services
2.3.4 CSL Limited Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CSL Limited Recent Developments/Updates
2.4 IBio Inc.
2.4.1 IBio Inc. Details
2.4.2 IBio Inc. Major Business
2.4.3 IBio Inc. Hereditary Angioedema Drug Product and Services
2.4.4 IBio Inc. Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 IBio Inc. Recent Developments/Updates
2.5 BioCryst Pharmaceuticals, Inc.
2.5.1 BioCryst Pharmaceuticals, Inc. Details
2.5.2 BioCryst Pharmaceuticals, Inc. Major Business
2.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
2.5.4 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 BioCryst Pharmaceuticals, Inc. Recent Developments/Updates
2.6 Ionis Pharmaceuticals, Inc.
2.6.1 Ionis Pharmaceuticals, Inc. Details
2.6.2 Ionis Pharmaceuticals, Inc. Major Business
2.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
2.6.4 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ionis Pharmaceuticals, Inc. Recent Developments/Updates
3.1 Global Hereditary Angioedema Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Hereditary Angioedema Drug Revenue by Manufacturer (2018-2023)
3.3 Global Hereditary Angioedema Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Hereditary Angioedema Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Hereditary Angioedema Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Hereditary Angioedema Drug Manufacturer Market Share in 2022
3.5 Hereditary Angioedema Drug Market: Overall Company Footprint Analysis
3.5.1 Hereditary Angioedema Drug Market: Region Footprint
3.5.2 Hereditary Angioedema Drug Market: Company Product Type Footprint
3.5.3 Hereditary Angioedema Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Hereditary Angioedema Drug Market Size by Region
4.1.1 Global Hereditary Angioedema Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Hereditary Angioedema Drug Consumption Value by Region (2018-2029)
4.1.3 Global Hereditary Angioedema Drug Average Price by Region (2018-2029)
4.2 North America Hereditary Angioedema Drug Consumption Value (2018-2029)
4.3 Europe Hereditary Angioedema Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Hereditary Angioedema Drug Consumption Value (2018-2029)
4.5 South America Hereditary Angioedema Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Hereditary Angioedema Drug Consumption Value (2018-2029)
5.1 Global Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
5.2 Global Hereditary Angioedema Drug Consumption Value by Type (2018-2029)
5.3 Global Hereditary Angioedema Drug Average Price by Type (2018-2029)
6.1 Global Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
6.2 Global Hereditary Angioedema Drug Consumption Value by Application (2018-2029)
6.3 Global Hereditary Angioedema Drug Average Price by Application (2018-2029)
7.1 North America Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
7.2 North America Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
7.3 North America Hereditary Angioedema Drug Market Size by Country
7.3.1 North America Hereditary Angioedema Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Hereditary Angioedema Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8.1 Europe Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
8.2 Europe Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
8.3 Europe Hereditary Angioedema Drug Market Size by Country
8.3.1 Europe Hereditary Angioedema Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Hereditary Angioedema Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9.1 Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Hereditary Angioedema Drug Market Size by Region
9.3.1 Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Hereditary Angioedema Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10.1 South America Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
10.2 South America Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
10.3 South America Hereditary Angioedema Drug Market Size by Country
10.3.1 South America Hereditary Angioedema Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Hereditary Angioedema Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11.1 Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Hereditary Angioedema Drug Market Size by Country
11.3.1 Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Hereditary Angioedema Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12.1 Hereditary Angioedema Drug Market Drivers
12.2 Hereditary Angioedema Drug Market Restraints
12.3 Hereditary Angioedema Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Hereditary Angioedema Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Hereditary Angioedema Drug
13.3 Hereditary Angioedema Drug Production Process
13.4 Hereditary Angioedema Drug Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Hereditary Angioedema Drug Typical Distributors
14.3 Hereditary Angioedema Drug Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Hereditary Angioedema Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Hereditary Angioedema Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pharming Group NV Basic Information, Manufacturing Base and Competitors
Table 4. Pharming Group NV Major Business
Table 5. Pharming Group NV Hereditary Angioedema Drug Product and Services
Table 6. Pharming Group NV Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pharming Group NV Recent Developments/Updates
Table 8. Takeda Basic Information, Manufacturing Base and Competitors
Table 9. Takeda Major Business
Table 10. Takeda Hereditary Angioedema Drug Product and Services
Table 11. Takeda Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Takeda Recent Developments/Updates
Table 13. CSL Limited Basic Information, Manufacturing Base and Competitors
Table 14. CSL Limited Major Business
Table 15. CSL Limited Hereditary Angioedema Drug Product and Services
Table 16. CSL Limited Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. CSL Limited Recent Developments/Updates
Table 18. IBio Inc. Basic Information, Manufacturing Base and Competitors
Table 19. IBio Inc. Major Business
Table 20. IBio Inc. Hereditary Angioedema Drug Product and Services
Table 21. IBio Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. IBio Inc. Recent Developments/Updates
Table 23. BioCryst Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. BioCryst Pharmaceuticals, Inc. Major Business
Table 25. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
Table 26. BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. BioCryst Pharmaceuticals, Inc. Recent Developments/Updates
Table 28. Ionis Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 29. Ionis Pharmaceuticals, Inc. Major Business
Table 30. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Product and Services
Table 31. Ionis Pharmaceuticals, Inc. Hereditary Angioedema Drug Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Ionis Pharmaceuticals, Inc. Recent Developments/Updates
Table 33. Global Hereditary Angioedema Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 34. Global Hereditary Angioedema Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 35. Global Hereditary Angioedema Drug Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 36. Market Position of Manufacturers in Hereditary Angioedema Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 37. Head Office and Hereditary Angioedema Drug Production Site of Key Manufacturer
Table 38. Hereditary Angioedema Drug Market: Company Product Type Footprint
Table 39. Hereditary Angioedema Drug Market: Company Product Application Footprint
Table 40. Hereditary Angioedema Drug New Market Entrants and Barriers to Market Entry
Table 41. Hereditary Angioedema Drug Mergers, Acquisition, Agreements, and Collaborations
Table 42. Global Hereditary Angioedema Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 43. Global Hereditary Angioedema Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 44. Global Hereditary Angioedema Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 45. Global Hereditary Angioedema Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 46. Global Hereditary Angioedema Drug Average Price by Region (2018-2023) & (USD/Unit)
Table 47. Global Hereditary Angioedema Drug Average Price by Region (2024-2029) & (USD/Unit)
Table 48. Global Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 49. Global Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 50. Global Hereditary Angioedema Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 51. Global Hereditary Angioedema Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 52. Global Hereditary Angioedema Drug Average Price by Type (2018-2023) & (USD/Unit)
Table 53. Global Hereditary Angioedema Drug Average Price by Type (2024-2029) & (USD/Unit)
Table 54. Global Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 55. Global Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 56. Global Hereditary Angioedema Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 57. Global Hereditary Angioedema Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 58. Global Hereditary Angioedema Drug Average Price by Application (2018-2023) & (USD/Unit)
Table 59. Global Hereditary Angioedema Drug Average Price by Application (2024-2029) & (USD/Unit)
Table 60. North America Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 61. North America Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 62. North America Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 63. North America Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 64. North America Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 65. North America Hereditary Angioedema Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 66. North America Hereditary Angioedema Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 67. North America Hereditary Angioedema Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 68. Europe Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Europe Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Europe Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 72. Europe Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 73. Europe Hereditary Angioedema Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 74. Europe Hereditary Angioedema Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Hereditary Angioedema Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 77. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 78. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 79. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 80. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 81. Asia-Pacific Hereditary Angioedema Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 82. Asia-Pacific Hereditary Angioedema Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 83. Asia-Pacific Hereditary Angioedema Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 84. South America Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 85. South America Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 86. South America Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 87. South America Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 88. South America Hereditary Angioedema Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 89. South America Hereditary Angioedema Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 90. South America Hereditary Angioedema Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 91. South America Hereditary Angioedema Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 92. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 93. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 94. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 97. Middle East & Africa Hereditary Angioedema Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 98. Middle East & Africa Hereditary Angioedema Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 99. Middle East & Africa Hereditary Angioedema Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 100. Hereditary Angioedema Drug Raw Material
Table 101. Key Manufacturers of Hereditary Angioedema Drug Raw Materials
Table 102. Hereditary Angioedema Drug Typical Distributors
Table 103. Hereditary Angioedema Drug Typical Customers
List of Figures
Figure 1. Hereditary Angioedema Drug Picture
Figure 2. Global Hereditary Angioedema Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Hereditary Angioedema Drug Consumption Value Market Share by Type in 2022
Figure 4. C1 Esterase Inhibitor Examples
Figure 5. Kallikrein Inhibitor Examples
Figure 6. Selective Bradykinin B2 Receptor Antagonist Examples
Figure 7. Global Hereditary Angioedema Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Hereditary Angioedema Drug Consumption Value Market Share by Application in 2022
Figure 9. Retail Pharmacies Examples
Figure 10. Hospital Pharmacies Examples
Figure 11. Online Pharmacies Examples
Figure 12. Global Hereditary Angioedema Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Hereditary Angioedema Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Hereditary Angioedema Drug Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Hereditary Angioedema Drug Average Price (2018-2029) & (USD/Unit)
Figure 16. Global Hereditary Angioedema Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Hereditary Angioedema Drug Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Hereditary Angioedema Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Hereditary Angioedema Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Hereditary Angioedema Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Hereditary Angioedema Drug Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Hereditary Angioedema Drug Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Hereditary Angioedema Drug Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Hereditary Angioedema Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Hereditary Angioedema Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Hereditary Angioedema Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Hereditary Angioedema Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Hereditary Angioedema Drug Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Hereditary Angioedema Drug Average Price by Type (2018-2029) & (USD/Unit)
Figure 31. Global Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Hereditary Angioedema Drug Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Hereditary Angioedema Drug Average Price by Application (2018-2029) & (USD/Unit)
Figure 34. North America Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Hereditary Angioedema Drug Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Hereditary Angioedema Drug Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Hereditary Angioedema Drug Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Hereditary Angioedema Drug Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Hereditary Angioedema Drug Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Hereditary Angioedema Drug Consumption Value Market Share by Region (2018-2029)
Figure 54. China Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Hereditary Angioedema Drug Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Hereditary Angioedema Drug Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Hereditary Angioedema Drug Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Hereditary Angioedema Drug Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Hereditary Angioedema Drug Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Hereditary Angioedema Drug Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Hereditary Angioedema Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Hereditary Angioedema Drug Market Drivers
Figure 75. Hereditary Angioedema Drug Market Restraints
Figure 76. Hereditary Angioedema Drug Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Hereditary Angioedema Drug in 2022
Figure 79. Manufacturing Process Analysis of Hereditary Angioedema Drug
Figure 80. Hereditary Angioedema Drug Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pharming Group NV Takeda CSL Limited IBio Inc. BioCryst Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc.
Related Reports
26 Aug 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
